Average Total Weight Loss of 23% With 14% Increase in Lean Body Mass After 12 Months All patients remained adherent to tirzepatide for the duration of the study NATICK, Mass. / Nov 25, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide... Read More

Case-controlled study in 1,143 patients demonstrates superior weight reduction, fat mass loss, and visceral fat loss with the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone Average weight reduction of 20% at 36 weeks, on par with bariatric surgery and high-dose GLP-1 therapy Improved body composition without adversely affecting muscle mass NATICK, Mass. / Nov 20, 2025 /... Read More

NATICK, Mass. / Nov 18, 2025 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with ProSurg Medical, a leading Brazilian medical device company specializing in bariatric and obesity care. This new partnership draws upon ProSurg Medical’s 30-year experience in the Brazilian market and reflects Allurion’s commitment... Read More

NATICK, Mass. / Nov 12, 2025 / Business Wire / Allurion Technologies, Inc . (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update. Recent Company Highlights Successfully passed U.S. Food and Drug Administration (“FDA”) Pre-Approval Inspection and Bioresearch Monitoring (BIMO) audit with zero observations and no Form 483 issued... Read More

Passing of key audits with zero findings and completion of Day-100 meeting are significant milestones in the FDA PMA process as the Company enters final stages of FDA review process for its Allurion Smart Capsule Exchange of outstanding debt for shares of convertible preferred stock would result in Company being debt-free $5M private placement financing with participation from new and existing stockholders and a strategic... Read More

NATICK, Mass. / Nov 06, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the third quarter 2025 on Wednesday, November 12, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access... Read More

Multicenter study across six countries demonstrates safety and efficacy of two consecutive treatments in adults with obesity Weight loss of greater than 20% on par with bariatric surgery and high dose GLP-1 therapy NATICK, Mass. / Oct 07, 2025 / Business Wire / Allurion Technologies, Inc . (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of the first peer-reviewed study on the... Read More

NATICK, Mass. / Sep 30, 2025 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its participation in the ROTH 4 th Annual Healthcare Opportunities Conference, which will be held on October 9, 2025 at the Metropolitan Club in New York City. Management will hold one-on-one meetings with investors throughout the day. Investors can register for the... Read More

NATICK, Mass. / Aug 13, 2025 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update. Recent Company Highlights and Outlook Announced new strategic direction focused on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry Signed term sheet with strategic... Read More

NATICK, Mass. / Aug 07, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access... Read More

Signed term sheet with strategic partner to enhance distribution capabilities and R&D pipeline, including the potential joint development of a novel, GLP-1 drug-eluting balloon Submitted protocol to IRBs for approval on prospective, multi-center trial on combination therapy with low-dose GLP-1s and the Allurion Program to achieve weight loss while maintaining muscle mass and increasing GLP-1 adherence Commenced transition to... Read More

In 522 patients, average weight loss was approximately 32 pounds at balloon passage and 31 pounds 1 year later, equating to approximately 95% weight maintenance In 497 patients, average weight loss was 14.3% of total body weight at balloon passage, with 86% of patients maintaining that weight loss 1 year later NATICK, Mass. / Jul 22, 2025 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically... Read More

NATICK, Mass. / Jul 09, 2025 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with Minogue Medical Inc., a leading Canadian medical device company specializing in bariatric and obesity care. This new partnership draws upon Minogue Medical’s 40-year experience in the Canadian market and reflects Allurion’s... Read More

Fourth and final module of the PMA submitted in June Supportive analyses included in final module of the PMA meet both of the pre-specified co-primary endpoints in the AUDACITY Study NATICK, Mass. / Jul 07, 2025 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced submission of the fourth and final module of the Pre-Market Approval (PMA) application to... Read More

Findings from two abstracts presented at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting reinforce the role of the AI-powered Allurion Program in delivering metabolically healthy weight loss Real-world experience in nearly 20,000 patients with the Allurion Program confirms significant fat loss while increasing lean body and muscle mass In one of the longest real-world studies of its kind,... Read More

NATICK, Mass. / May 29, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation will take place on Wednesday, June 4 at 3:45 p.m. ET. A webcast of the... Read More

In 1,962 patients treated in France with the Allurion Program, muscle mass as a percentage of total body weight increased, on average, by 6.6% and fat mass decreased, on average, by 11% Company announces that shipments to France have resumed, and patient treatments are expected to resume next month NATICK, Mass. / May 27, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer... Read More

NATICK, Mass. / May 14, 2025 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook Maintaining 2025 revenue guidance of approximately $30 million with a reduction of approximately 50% in operating expenses compared... Read More

Four abstracts presented at the European Congress on Obesity Data indicate potential synergies of Allurion’s swallowable Procedureless TM intragastric balloon (the “Allurion Balloon”) and Virtual Care Suite (VCS) (together, the “Allurion Program”) with normal dosing of GLP-1s, building upon previous data on the combination of the Allurion Program with low-dose GLP-1s GLP-1s used in combination with the VCS lead to an average... Read More

NATICK, Mass. / May 05, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference... Read More

Meeting to Now be Held on Thursday, April 10, 2025 at 12:00 pm Via Live Audio Webcast NATICK, Mass. / Apr 03, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that its Special Meeting of Stockholders (the “Special Meeting”), originally scheduled for Friday, April 4, 2025, has been postponed. The Special Meeting is now... Read More

NATICK, Mass. / Mar 26, 2025 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. Recent Company Highlights and Outlook Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing... Read More

Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy NATICK, Mass. / Mar 20, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence. 52 patients... Read More

NATICK, Mass. / Mar 12, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the fourth quarter 2024 on Wednesday, March 26, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the... Read More

Patent portfolio now exceeds 60 issued patents globally NATICK, Mass. / Mar 04, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled “Automatic-Sealing Balloon-Filling... Read More

NATICK, Mass. / Feb 25, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences. Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at 9:10 a.m. ET and host one-on-one investor meetings throughout the day on March 3, 2025, at the 45 th Annual TD... Read More

NATICK, Mass. / Feb 20, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 900,000 shares of the Company’s common stock at a price of $5.23 per share and warrants to purchase up to 1,800,000 shares of... Read More

NATICK, Mass. / Feb 19, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 900,000 shares of the Company’s common stock at a price of $5.23 per share in a registered direct offering. In addition,... Read More

NATICK, Mass. / Feb 18, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 agonists. The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term... Read More

ANSM, the French regulatory authority, clears Allurion to resume sales of the Allurion Balloon Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and GLP-1s to prevent muscle loss NATICK, Mass. / Feb 13, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the... Read More

NATICK, Mass. / Jan 24, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,240,000 shares of the Company’s common stock at a price of $6.00 per share in a registered direct offering priced... Read More

NATICK, Mass. / Jan 23, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition. Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass... Read More

NATICK, Mass. / Jan 21, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) dated January 15, 2025 for U.S. Patent No. 12,209,677 titled “Binary Fluid Control Valve System”. This patent covers additional claims for an enhanced,... Read More

NATICK, Mass. / Jan 14, 2025 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments, LP (“RTW”) for the purchase and sale of 841,751 shares of the Company’s common stock in a private placement at a purchase price of $2.97 per share. The private... Read More

At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favorable safety profile of the Allurion Balloon Fourth and final module of PMA submission including AUDACITY trial data planned for 2025 NATICK, Mass.--( BUSINESS WIRE )-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending... Read More

NATICK, Mass. / Dec 24, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The reverse stock split will take effect at 12:01 a.m. Eastern Time on January... Read More

NATICK, Mass. / Dec 02, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the Listings Operations Committee of the New York Stock Exchange (the “NYSE”) stating that the NYSE has accepted the Company’s previously submitted plan to regain compliance with the NYSE’s continued listing standard set forth in Section... Read More

AllurionMeds is designed to address a critical demand from patients: The Weight Must Stay Off Features Coach Iris, a first-of-its-kind conversational AI behavioral agent for weight loss and maintenance, trained using real-world experience in over 150,000 patients Compounded GLP-1 program designed to provide long-term behavioral change while addressing weight re-gain and other negative side effects for patients Expands... Read More

NATICK, Mass. / Nov 13, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. Recent Company Highlights Revenue of $5.4 million, which includes a reduction of $1.2 million for product recalled from France during the third quarter... Read More

19,428 patients treated with the Allurion Program across 72 countries lost an average of 12.2% of total body weight NATICK, Mass. / Nov 04, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the presentation of two abstracts at Obesity Week 2024, the annual meeting of The Obesity Society. The first abstract comprises outcomes data from Allurion’s largest... Read More

NATICK, Mass. / Oct 30, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the... Read More

NATICK, Mass. / Oct 23, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the submission of the first three modules of its premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for the Allurion Balloon. The Company expects to file the fourth and final module of the PMA containing the clinical data from its AUDACITY trial early... Read More

In a study of 167 patients, average weight reduction was 15.7% at four months, 17.1% at six months, and 14.7% at one year Body fat percentage decreased at six months with no change in muscle mass NATICK, Mass. / Oct 09, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study in the journal Clinical Obesity on the impact of the Allurion... Read More

Systematic review of 11 studies involving 2,107 patients reports average weight reduction of 12.5% with significant improvements in metabolic health NATICK, Mass. / Oct 01, 2024 / Business Wire / Allurion Technologies, Inc . (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a systematic review and meta-analysis evaluating the effectiveness and safety of the Allurion Program. The analysis... Read More

NATICK, Mass. / Sep 05, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE’s continued listing standards because the average market capitalization of the Company was less than $50.0 million... Read More

In a study of 91 adolescents, average weight loss was 13.1% at four months with no serious adverse events NATICK, Mass. / Sep 05, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study on the safety and effectiveness of the Allurion Program in adolescents. In the study, 91 adolescents between 15 and 17 years-old with average body mass... Read More

Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market NATICK, Mass. / Sep 03, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we... Read More

Average weight reduction in 486 patients improved from 10.5% at four months to 13.7% at one year on the Allurion Program Separate studies with patients on GLP-1 therapy report significant weight re-gain after discontinuation of drug and lifestyle intervention program NATICK, Mass. / Aug 28, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication... Read More

Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands NATICK, Mass. / Aug 20, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company’s international... Read More

NATICK, Mass. / Aug 15, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the NYSE’s continued listing standards because the average closing price of the Company’s common stock per the Notice was less... Read More

Results highlighted by strong sequential revenue growth and record procedure volume NATICK, Mass. / Aug 13, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the second quarter ended June 30, 2024 and provided a business update. Recent Company Highlights Second quarter revenue of $11.8 million, a... Read More

NATICK, Mass. / Jul 16, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the second quarter 2024 on Tuesday, August 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the... Read More

NATICK, Mass. / Jun 28, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the pricing of an underwritten public offering of 14,406,508 shares of its common stock, par value $0.0001 per share (the “Shares”), and warrants to purchase 14,406,508 Shares (the “Warrants” and, together with the Shares, the “Securities”) at a public... Read More

NATICK, Mass. / Jun 26, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it has launched an underwritten public offering of up to $20 million of its common stock, par value $0.0001 per share (the “Shares”), and warrants to purchase Shares (the “Warrants” and, together with the Shares, the “Securities”). Jefferies and TD... Read More

Patients gained an average of 5.6% in lean body mass during the Allurion Program Separate studies of patients on GLP-1 therapy report an average lean mass loss of 11% 1 NATICK, Mass. / Jun 20, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss... Read More

New data show 22.1% weight loss at one year with consecutive Allurion Balloons, approaching weight loss surgery outcomes NATICK, Mass. / Jun 11, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS) taking place in San Diego, California, June 9-13,... Read More

NATICK, Mass. / Jun 05, 2024 / Business Wire / Allurion Technologies, Inc . (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company’s Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and... Read More

Company also announces first commercial agreements for the Virtual Care Suite in the United States NATICK, Mass. / May 30, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the expansion of its Artificial Intelligence (AI)-powered weight loss coach, Coach Iris , to support patients prescribed GLP-1s and other anti-obesity medications and the first... Read More

NATICK, Mass. / May 29, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences: Jefferies Global Healthcare Conference Sidoti Small Cap Virtual Conference About Jefferies Global Healthcare Conference Allurion’s Chief Executive Officer, Shantanu Gaur, and Chief Financial Officer, Chris Geberth,... Read More

New data demonstrate significant fat mass loss while preserving lean mass NATICK, Mass. / May 15, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the 31 st European Congress on Obesity (ECO) held in Venice, Italy, on 12-15 May, 2024. Presentations include data from a study of 712 patients treated with the Allurion... Read More

NATICK, Mass. / May 14, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial results for the first quarter ended March 31, 2024, and provided a business update. Recent Company Highlights First quarter revenue of $9.4 million, an increase of 14% from the fourth quarter of 2023 and in line with preannouncement on... Read More

New data demonstrates 80% sustained weight loss at three years with the Allurion Program and initial positive outcomes of a novel, generative AI-powered conversational agent for obesity treatment NATICK, Mass. / May 02, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three oral scientific presentations at the 12 th Congress of the International... Read More

Generated quarter-over-quarter revenue growth and continued growth in procedural volume, while substantially reducing cash burn Company to report full first quarter 2024 financial results on May 14, 2024 NATICK, Mass. / Apr 30, 2024 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced preliminary, unaudited results for the first... Read More

Simplifies capital structure through prepayment of existing term loan Reduces annual interest expense, providing increased near-term cash flow and operational flexibility Extends expected cash runway in advance of AUDACITY FDA trial read-out Strengthens long-term partnership with RTW Investments NATICK, Mass. / Apr 17, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company... Read More

Virtual Care Suite (VCS) is now available to license in the United States for providers offering GLP-1 and other anti-obesity medication therapy, bariatric surgery, and weight loss devices US product launch to kick off at the Obesity Medicine Conference in Denver on April 25 NATICK, Mass. / Apr 04, 2024 / Business Wire / Allurion Technologies, Inc . (NYSE: ALUR), a company dedicated to ending obesity, today announced the... Read More

NATICK, Mass. / Mar 21, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion”), a company dedicated to ending obesity, today reported financial results for the fourth quarter and full year ended December 31, 2023, and reiterated 2024 guidance. Fourth Quarter Highlights and Outlook Reiterating 2024 guidance on procedural volume, revenue, gross margin, and cash burn Fourth quarter revenue of $8.2 million... Read More

NATICK, Mass. / Mar 13, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in the 34 th Annual Oppenheimer Healthcare MedTech & Services Conference, taking place on March 12 - 13, 2024, virtually. Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will present today, Wednesday, March... Read More

NATICK, Mass. / Mar 12, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of its newest board member and Audit Committee Chair, Milena Alberti-Perez, effective as of March 11, 2024. "Milena joins the Allurion board during an exciting time in the company’s history and is a proven and dynamic leader, with deep experience as an operator and... Read More

NATICK, Mass. / Mar 04, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the fourth quarter 2023 on Thursday, March 21, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please... Read More

NATICK, Mass. / Feb 20, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in the 44 th Annual Cowen Health Care Conference, taking place on March 4 – March 6, 2024 at the Marriott Copley Place in Boston, Massachusetts. Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will present... Read More

NATICK, Mass. / Feb 08, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in the BTIG Snowbird Conference taking place on Monday, February 12 through Wednesday, February 14, 2024 in Snowbird. Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will be available for investor 1x1... Read More

NATICK, Mass. / Jan 29, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Brendan Gibbons as its new Chief Legal Officer and corporate secretary. Brendan joins Allurion with nearly 20 years’ experience as a chief legal and compliance officer at three separate public companies. Most recently, Brendan served as Executive Vice President and... Read More

Allurion Program is the latest innovation in the NHS’s war against obesity NATICK, Mass. / Jan 23, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that the Somerset NHS Foundation Trust (FT) is the first NHS trust in the United Kingdom, and the first non-private sector organisation in the world, to introduce the Allurion Gastric Balloon - the world's... Read More

Company inks deals with Lazeo and Transform, two of Europe’s largest aesthetic and weight loss groups NATICK, Mass. / Jan 17, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced further expansion of its Virtual Care Suite (VCS) digital platform with new commercial agreements signed with Lazeo , France's largest aesthetic and weight loss clinic chain, and... Read More

Allurion Program led to resolution of type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months in over half of the patients treated Results improved with addition of oral GLP-1 agonist semaglutide NATICK, Mass. / Jan 11, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a randomized, double-blind study in Obesity... Read More

Generated substantial procedure growth in 2023 driven by best-in-class efficacy of balloon program; prioritizing key investments in strategic markets and digital innovations ahead of FDA milestones NATICK, Mass. / Jan 08, 2024 / Business Wire / Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced preliminary unaudited results for the fourth quarter and... Read More

First of its kind research investigated the impact of the changing weight-loss market on the Allurion Program Research included 172 healthcare professionals (HCPs) and 1663 patients across 64 countries Almost 90% of HCPs believed the Allurion Program was an ideal first-line treatment to achieve >10% body weight loss in a fast and sustainable way NATICK, Mass. / Jan 05, 2024 / Business Wire / Allurion Technologies, Inc.... Read More

Company also announces addition of serial entrepreneur Brian Conyer to the team to lead commercialization of Allurion’s digital assets NATICK, Mass. / Jan 02, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced an expanded commercial agreement with Weight Doctors® —Germany’s leading group of private clinics and centers for weight loss—and the hiring of Brian... Read More

Completed NYSE listing and business combination generating $92M in net proceeds Generated 40% sequential revenue growth in first quarter as a public company Completed enrollment in AUDACITY FDA pivotal trial for Allurion Balloon Launched Coach Iris, a conversational, 24/7, and generative AI-powered weight loss coach NATICK, Mass. / Nov 13, 2023 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion”), a... Read More

NATICK, Mass. / Nov 06, 2023 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in the Jefferies London Healthcare Conference taking place on November 14-16, 2023 in London. Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will present on Wednesday, November 15, 2023 at 9:30 a.m. GMT,... Read More

NATICK, Mass. / Nov 06, 2023 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2023 on Monday, November 13, 2023. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please... Read More

AUDACITY trial to support FDA approval of the Allurion Balloon NATICK, Mass. / Oct 11, 2023 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the completion of patient enrollment in its AUDACITY trial. AUDACITY is a randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) approval of the Allurion Balloon. The trial... Read More

Research highlights cutting-edge applications of AI and behavioral science to automate care and new data on treatment in overweight patients without obesity NATICK, Mass. / Oct 04, 2023 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced acceptance of five abstracts that will be presented at Obesity Week 2023, the annual meeting of The Obesity Society to be held... Read More

Congress convenes the world’s leading bariatric healthcare professionals to discuss innovative therapies NATICK, Mass. / Sep 18, 2023 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced its participation in the 4 th International Bariatric Club (IBC) Oxford World Congress, which takes place at Oxford University, September 18-20, 2023. The IBC event, entitled... Read More

Powered by GPT and Fine-Tuned to Allurion’s Proprietary Behavior Change Program Allurion invites attendees of the IFSO conference in Naples, Italy (August 30 to September 1, 2023) to experience Coach Iris at booth #509-510 NATICK, Mass. / Aug 29, 2023 / Business Wire / Allurion Technologies, Inc . (NYSE: ALUR), a company dedicated to ending obesity, has today unveiled Coach Iris, a new generative AI-powered health coach... Read More

New data includes a study in over 5,000 patients—the largest intragastric balloon weight loss study ever conducted NATICK, Mass. / Aug 28, 2023 / Business Wire / Allurion (NYSE: ALUR), a company dedicated to ending obesity, today announced the acceptance of nine scientific presentations at the upcoming 26th World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). These... Read More